Marie de Bakker, Teun B Petersen, Anja J Rueten-Budde, K Martijn Akkerhuis, Victor A Umans, Jasper J Brugts, Tjeerd Germans, Marcel J T Reinders, Peter D Katsikis, Peter J van der Spek, Rachel Ostroff, Ruicong She, David Lanfear, Folkert W Asselbergs, Eric Boersma, Dimitris Rizopoulos, Isabella Kardys
AIMS: Risk assessment tools are needed for timely identification of patients with heart failure (HF) with reduced ejection fraction (HFrEF) who are at high risk of adverse events. In this study, we aim to derive a small set out of 4210 repeatedly measured proteins, which, along with clinical characteristics and established biomarkers, carry optimal prognostic capacity for adverse events, in patients with HFrEF. METHODS AND RESULTS: In 382 patients, we performed repeated blood sampling (median follow-up: 2...
December 2023: European heart journal. Digital health